Minerva Neurosciences (NERV) Operating Leases (2019 - 2020)
Minerva Neurosciences' (NERV) quarterly Operating Leases came in at $16288.0 in Q2 2020, down 91.9% YoY from $201066.0 in Q3 2019, and down 74.69% on a QoQ basis from $64350.0 in Q1 2020.
Powered by 
Analysis
Minerva Neurosciences (NERV) Operating Leases (2019 - 2020) Analysis & Trends
Minerva Neurosciences (NERV) has 2 years of Operating Leases data on file, last reported at $16288.0 in Q2 2020.
- Quarterly Operating Leases fell 91.9% year-over-year to $16288.0 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $16288.0 (down 91.9% YoY) and the FY2019 annual result came in at $111229.0, changed N/A from the prior year.
- Operating Leases eased to $16288.0 in Q2 2020, from $64350.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $243115.0 in Q1 2019 to a low of $16288.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | 16,288.00 |
| Mar 31, 2020 | 64,350.00 |
| Dec 31, 2019 | 111,229.00 |
| Sep 30, 2019 | 156,956.00 |
| Jun 30, 2019 | 201,066.00 |
| Mar 31, 2019 | 243,115.00 |